GRAIL, Inc. — Investor Relations & Filings
Filings indexed
199
across all filing types
Latest filing
2026-06-01
Board/Management Inform…
Country
US
United States of America
Listing
US
GRAL
GRAIL, Inc. is a healthcare company dedicated to detecting cancer early. Its mission is to reduce the global burden of cancer through early diagnosis when treatment may be more effective. The company's flagship product is the Galleri® test, a blood-based multi-cancer early detection (MCED) test. The Galleri test is designed to screen for a signal shared by multiple types of cancer, including many that lack recommended screening methods, often before symptoms appear. GRAIL develops its technology by leveraging next-generation sequencing (NGS), machine learning, and data from population-scale clinical studies. The company's focus is on identifying deadly cancers in their initial stages to improve patient outcomes.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-06-01 | English | |
| DEF 14A - GRAIL, Inc. (0001699031) (Filer) | 2026-04-28 | English | |
| SCHEDULE 13G/A - GRAIL, Inc. (0001699031) (Subject) | 2026-03-27 | English | |
| 4 - GRAIL, INC. (0001699031) (Filer) | 2026-03-04 | English | |
| 4 - GRAIL, INC. (0001699031) (Filer) | 2026-03-04 | English | |
| 4 - GRAIL, INC. (0001699031) (Filer) | 2026-03-04 | English |
Browse filings by year
9 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
14 filings
| |||||
| 47923163 | 8-K | 2026-06-01 | English | ||
| 38160818 | DEF 14A - GRAIL, Inc. (0001699031) (Filer) | 2026-04-28 | English | ||
| 33060498 | SCHEDULE 13G/A - GRAIL, Inc. (0001699031) (Subject) | 2026-03-27 | English | ||
| 32896830 | 4 - GRAIL, INC. (0001699031) (Filer) | 2026-03-04 | English | ||
| 32896829 | 4 - GRAIL, INC. (0001699031) (Filer) | 2026-03-04 | English | ||
| 32896831 | 4 - GRAIL, INC. (0001699031) (Filer) | 2026-03-04 | English | ||
| 32896832 | 8-K - GRAIL, INC. (0001699031) (Filer) | 2026-02-19 | English | ||
| 31355626 | SCHEDULE 13G Filing | 2026-02-17 | English | ||
| 31355656 | SCHEDULE 13G/A Filing | 2026-02-11 | English | ||
| 31355567 | SCHEDULE 13G/A Filing | 2026-02-09 | English | ||
| 13013383 | FORM 4 | 2026-01-16 | English | ||
| 13013385 | FORM 4 | 2026-01-16 | English | ||
| 13013386 | FORM 4 | 2026-01-16 | English | ||
| 13013388 | 8-K | 2026-01-12 | English | ||
|
2025
1 filing
| |||||
| 13013387 | FORM 4 | 2025-12-05 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
TuHURA Biosciences, Inc./NV
A Phase 3 immuno-oncology company developing therapies for …
|
HURA | US | Professional, scientific and te… |
|
Tyra Biosciences, Inc.
Clinical-stage biotech developing precision medicines targe…
|
TYRA | US | Professional, scientific and te… |
|
UCAR
A nonprofit consortium of universities advancing atmospheri…
|
ALUCR | FR | Professional, scientific and te… |
|
Ulisse Biomed
Develops an integrated platform for distributed and connect…
|
UBM | IT | Professional, scientific and te… |
|
UnicoCell
Develops stem cell therapies and provides CDMO services for…
|
6794 | TW | Professional, scientific and te… |
|
UNIVERSAL DISPLAY CORP \PA\
Researches, develops, and supplies OLED technologies and ma…
|
OLED | US | Professional, scientific and te… |
|
Urteste S.A.
Develops non-invasive urine tests for the early detection o…
|
URT | PL | Professional, scientific and te… |
|
VALIRX PLC
Life science company developing therapeutics for oncology a…
|
VAL | GB | Professional, scientific and te… |
|
Vanta Bioscience Limited
A contract research organization providing preclinical safe…
|
540729 | IN | Professional, scientific and te… |
|
Vaxil Bio Ltd.
Uses a proprietary Signal Peptide platform to develop immun…
|
VXL | CA | Professional, scientific and te… |
GRAIL, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/31638/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=31638 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=31638 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=31638 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 31638}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for GRAIL, Inc. (id: 31638)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.